Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers
- 9 June 2006
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 62 (7) , 513-521
Abstract
To describe in detail the intravenous, single oral and multiple oral dose enantioselective pharmacokinetics of tramadol in CYP2D6 extensive metabolizers (EMs) and poor metabolizers (PMs). Eight EMs and eight PMs conducted three phases as an open-label cross-over trial with different formulations; 150 mg single oral tramadol hydrochloride, 50 mg single oral tramadol hydrochloride every 8 h for 48 h (steady state), 100 mg intravenous tramadol hydrochloride. Urine and plasma concentrations of (+/−)-tramadol and (+/−)-M1 were determined for 48 h after administration. In all three phases, there were significant differences between EMs and PMs in AUC and t1/2 of (+)-tramadol (P≤0.0015), (−)-tramadol (P≤0.0062), (+)-M1 (P≤0.0198) and (−)-M1 (P≤0.0370), and significant differences in Cmax of (+)-M1 (PP≤0.0010). In Phase A and C, significant differences in tmax were seen for (+)-M1 (P≤0.0200). There were no statistical differences between the absolute bioavailability of tramadol in EMs and PMs. The urinary recoveries of (+)-tramadol, (−)-tramadol, (+)-M1 and (−)-M1 were statistically significantly different in EMs and PMs (PO-demethylation of tramadol was catalysed stereospecific by CYP2D6 in the way that very little (+)-M1 was produced in PMs.Keywords
This publication has 43 references indexed in Scilit:
- The Analgesic Effect of Tramadol After Intravenous Injection in Healthy Volunteers in Relation to CYP2D6Anesthesia & Analgesia, 2006
- Metabolism of the analgesic drug ULTRAM ® (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolitesXenobiotica, 2002
- Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolutionPharmacogenetics, 1997
- Cloning and sequencing of a new non-functional CYP2D6 allele: Deletion of T1795 in exon 3 generates a premature stop codonPharmacogenetics, 1994
- Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotypeHuman Molecular Genetics, 1994
- TramadolDrugs, 1993
- Debrisoquine oxidation polymorphismPharmacogenetics, 1993
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics, 1991
- Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature, 1990
- Sparteine Oxidation Polymorphism in DenmarkActa Pharmacologica et Toxicologica, 1985